Market News

November 27, 2012  Tue 7:23 AM CT

Primary and Secondary Endpoints Are Met

Acadia Phaemaceuticals announced successful top-line results for the Phase III trial of its Pimavanserin drug for patients with Parkinson’s disease psychosis. The compound met the primary endpoint by demonstrating highly significant antipsychotic efficacy using a nine-item scale. It also met a secondary endpoint for motoric tolerability. ACAD is up 160 percent before the bell on my tradeMONSTER platform!

Ralcorp Accepts ConAgra Takeover Offer

Ralcorp agreed to be purchased by ConAgra for $90 a share in cash. That's a nice premium for RAH, which closed at $70.23 yesterday, and the stock is up almost 27 percent in early trading.

Las Vegas Sands Rallies on Special Dividend

Las Vegas Sands announced that its board approved a special dividend of $2.75 a share in cash. LVS climbs more than 4 percent in the premarket.

News Archives
OptionsHouse

Education & Strategy

From the AP Archives: If It's Not There...

I have talked at great length about the fact that as an individual investor, you do not have to be in the market at all times.

More education articles »